COVID Vaccine Confidence Requires Radical Transparency
Public trust in a potential vaccine is under threat. Drug companies and their academic partners must disclose protocols and results data.
Send us a link
Public trust in a potential vaccine is under threat. Drug companies and their academic partners must disclose protocols and results data.
Recent advances are bringing cancer vaccines much closer to reality, giving patients another weapon in their arsenal of cancer treatments, according to Dr Madiha Derouazi, CEO of Amal Therapeutics and one of three winners of the 2020 EU Prize for Women Innovators.
Immunization has always been a proxy for wider fears about social control, a history reminds us.
Researchers stress need for antenatal care, as emerging data link disrupted pregnancy services to increase in stillbirths.
Tear gas from the near-nightly sieges in Portland may be trickling into the Willamette River, officials fear.
We do not have to live in a constant state of fear that our health is being put at-risk. We can restore and strengthen science-based decision-making processes that are protected from political interference. Today, we are releasing our first set of recommendations providing a roadmap for how the fede
The order to reroute CDC hospitalization figures raised accuracy concerns. But that's just one of the problems with how the country collects health data.
Just weeks after resolving shortages in swabs, researchers are struggling to find the chemicals and plastic pieces they need to carry out coronavirus tests in the lab - leading to long waiting times.
The University of Oxford candidate, led by Sarah Gilbert, might be through human trials in September. AstraZeneca has lined up agreements to produce 2 billion doses. Could this be the one?
Public health messaging and science have to work hard to stay in sync during a crisis. During the Covid-19 pandemic, they haven't always succeeded.
There is a preprint with data on the first coronavirus vaccine candidate from the Pfizer/BioNTech effort. This article argues that it's extremely important that the human trial data is made available for the public to trust the vaccines that get approved.
It’s not the first time masculine ideology has driven resistance to a public health initiative.
It is likely we'll eventually have a coronavirus vaccine - but perhaps not as quickly as some expect. From development, to clinical trials and distribution, ProPublica reporter Caroline Chen explains the tremendous challenges that lie ahead.
A virologist helped crack an impossible problem: how to insure against the economic fallout from devastating viral outbreaks. The plan was ingenious. Yet we're still in this mess.
Surgisphere, whose employees appear to include a sci-fi writer and adult content model, provided database behind Lancet and New England Journal of Medicine hydroxychloroquine studies.
If President Trump sidelines the World Health Organization, experts foresee incoherence, inefficiency and resurgence of deadly diseases.
Inside the U.S. and Panama's long-running collaboration to rid an entire continent of a deadly disease.
Scientists say the microbe - found in the wild near Lake Victoria - has enormous potential.
What does it mean for science - and public health - that scientific journals are now publishing research at warp speed?
Researchers believe they could pre-emptively create vaccines and drugs to fight a wide range of viral threats - if they can get sufficient funding.
Nassim Nicholas Taleb is frustrated whenever the coronavirus crisis is referred to by the term he coined for an unpredictable, rare catastrophe.
Public green spaces are good for the immune system and the mind-and they can be rationed to allow for social distancing.
The Environmental Protection Agency moved today to restrict the types of research that can be used in public health protection decisions and scientific assessments. In the midst of the coronavirus pandemic, the agency is recklessly giving the public just 30 days to comment on this sweeping proposal.
To help manage the shortage, the authorities sent a message that made them untrustworthy.
For a variety of reasons, researchers want to figure out who's most at risk of being infected and who's most at risk of developing severe illness.
The vast majority of the discourse among the punditry and policymakers is about ensuring we have the right response. Shouldn't we instead be asking a more fundamental question: How did this happen in the first place?
Women mount stronger immune responses to infection, scientists say. And in China, men smoke in much greater numbers.
Public health scientists who have closely followed the emergence of 2019 novel coronavirus disease (COVID-19) are deeply concerned about its impact on global health and wellbeing.
Up-to-the-minute reports and statistics can unintentionally distort the facts.
Experiments lost as labs remain closed; scientific meetings canceled or postponed.